Ford Motor Company (NYSE:F) and Petty’s Garage are teaming up to build a new 627-horsepower Mustang GT a limited-edition fastback inspired by the popular Petty’s Garage Mustang GT on display at last year’s SEMA show in Las Vegas. On Thursday shares of Ford Motor Company (NYSE:F) closed at $16.43. Company’s sales growth for last 5 years was 0.50% and EPS growth for next 5 years is recorded as 17.10%.
Enzymotec Ltd. (NASDAQ:ENZY) announced net revenues decreased 41.0% to $14.2 million from $24.1 million for the fourth quarter of 2013.For the fourth quarter of 2014, based on the equity method of accounting, net revenues decreased 41.8% to $10.8 million from $18.5 million for the fourth quarter of 2013. Enzymotec Ltd. (NASDAQ:ENZY) in last trading activity fell -4.78% to close at $6.58. Company weekly performance is 16.67% while its quarterly performance stands at -21.29%. Enzymotec Ltd. (NASDAQ:ENZY) is -77.88% away from its 52 week high.
On February 13, 2015, the Compensation Committee of the Board of Directors of SL Industries, Inc. (NYSEMKT:SLI) adopted the 2015 Bonus Plan to provide incentives to officers and members of management of the Company and its subsidiaries, including certain of the Company’s executive officers, in the form of equity grants and cash bonus payments for achieving certain performance goals established for them. On last trading day SL Industries, Inc. (NYSEMKT:SLI) fell -0.63% to close at $40.49. Its volatility for the week is 4.56% while volatility for the month is 4.81%. SLI’s sales growth for past 5 years was 1.90% and its EPS growth for past 5 years was 23.40%. SL Industries, Inc. (NYSEMKT:SLI) monthly performance is -3.38%.
Daqo New Energy Corp. (NYSE:DQ) has 5.33% insider ownership while its institutional ownership stands at 25.60%. In last trading activity company’s stock closed at $20.22.
Ocera Therapeutics, Inc. (NASDAQ:OCRX) announced preliminary topline results from a Phase 2a investigator-sponsored study evaluating the company’s drug candidate OCR-002 versus placebo in patients with upper gastrointestinal bleeding (UGIB) associated with liver cirrhosis. On last trading day Ocera Therapeutics, Inc. (NASDAQ:OCRX) moved up 1.78% to close at $6.30. Its volatility for the week is 7.89% while volatility for the month is 6.23%. OCRX’s EPS growth for past 5 years was 25.60%. Ocera Therapeutics, Inc. (NASDAQ:OCRX) monthly performance is 3.96%.